Q-omics provides the consensus-scored NIBAN2 profile across patient tissues and cancer cell-line models. NIBAN2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NIBAN2 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, NIBAN2 protein abundance shows 23,028 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRP, and GBM as cancer lineages where NIBAN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIBAN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIBAN2 survival associations across molecular data types. NIBAN2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIBAN2 RNA expression–survival associations across cancer types. High NIBAN2 expression shows unfavorable associations in MESO, BLCA, BRCA, PAAD and LUSC, but favorable associations in DLBC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NIBAN2 RNA expression.
This table summarizes NIBAN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NIBAN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIBAN2 shows lower tumor expression in LUAD and KICH and higher tumor expression in KIRP, BRCA, CHOL and LIHC. The KIRP box plot shows higher NIBAN2 RNA expression in tumor versus normal tissue (log2 FC = +1.368, t-test p < 0.001).
This table shows molecular features associated with NIBAN2 in patient tissues and cancer cell lines. In patient samples, NIBAN2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NIBAN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
